Becton Dickinson (BDX)
NYSEHealth CareMedical Instruments & SuppliesSnapshot 2026-07-07
$156.30+0.49%
Close 2026-07-07 · 1-day change
Reading BDX? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track BDX free→NYSEHealth CareMedical Instruments & SuppliesSnapshot 2026-07-07
Reading BDX? This analysis is rebuilt every market day. Get it tracked free. No credit card.
Track BDX free→Intact: The reason to own it still holds.
Becton Dickinson is a stable medical device company growing revenue about 5% yearly. It keeps beating earnings estimates with EPS around $12.6 next year. The company returns cash to shareholders with $2.2 billion in buybacks and dividends. Its valuation is cheap compared to peers with a PE of 11.6 versus 36.5.
Revenue growth could slow below 0% as analysts expect a 9% decline next year. Management is volatile and guidance is soft, which may hurt confidence. The company’s share repurchase progress is mixed and debt repayment plans are uncertain.
The market prices in about 9% revenue decline and the stock trades 29% below our fair value near $220. Our fair value is 26% above the Street median, reflecting more optimism on growth and valuation.
Breaks if: Capital returned falls below $2 billion annually
Utilize $2 billion from cash distribution for share repurchases through an accelerated share repurchase program.
Standing thesis, reviewed periodically — not a price target or advice.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Stated in 3 of last 3 quarters. BD returned $2.2 billion to shareholders in FY25 through dividends and share repurchases. The company plans to use $2 billion from recent transactions for an accelerated share repurchase program. Persistent statement, limited substantive delivery this quarter as the program is ongoing.
“BD expects to use $2 billion of the proceeds to repurchase BD common shares through an accelerated share repurchase program.”
“Returned $2.2 billion to shareholders in FY25 through dividends and share repurchases.”
“Expects to complete remaining $250 million of $1 billion share buyback commitment by the end of fiscal 2025.”
Breaks if: Debt repayment from cash distribution falls below $1 billion
Use $2 billion from cash distribution for debt repayment.
Breaks if: EPS guidance falls below $12.5 for FY26
Breaks if: YoY revenue growth falls below 0% next year
Complete the spin-off of the Biosciences and Diagnostic Solutions business and combine it with Waters Corporation.